Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hansoh Pharmaceutical Group CoHNSPF 91 Debt-to-EBITDA is 0.02 as of Dec. 2025, which is 33% below its 10-year median of 0.03. GuruFocus rates HNSPF with a GF Score™ of 91/100 and a GF Value™ of $3.52 (Modestly Overvalued). Among 691 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 97.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Debt-to-EBITDA or its related term are showing as below:
HNSPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 1.31
Current: 0.02
During the past 10 years, the highest Debt-to-EBITDA Ratio of Hansoh Pharmaceutical Group Co was 1.31. The lowest was 0.00. And the median was 0.03.
HNSPF's Debt-to-EBITDA is ranked better than 97.4% of 691
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs HNSPF: 0.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hansoh Pharmaceutical Group Co Debt-to-EBITDA Related Terms
Hansoh Pharmaceutical Group Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Hansoh Pharmaceutical Group Co (HNSPF) has a Debt-to-EBITDA of 0.02 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hansoh Pharmaceutical Group Co. This is 33% below median its historical median of 0.03. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #18 out of 691 companies in the Drug Manufacturers industry, placing it in the top 2.6%.
Is Hansoh Pharmaceutical Group Co's Debt-to-EBITDA too high?
Hansoh Pharmaceutical Group Co's current Debt-to-EBITDA of 0.02 is 33% below median its 10-year median of 0.03. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Hansoh Pharmaceutical Group Co's value of 0.02 is 98.8% below this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #18 out of 691 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #18 out of 691 companies for Debt-to-EBITDA. This places Hansoh Pharmaceutical Group Co in the top 3% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. Hansoh Pharmaceutical Group Co's value of 0.02 is 98.8% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 1.64, Hansoh Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current Debt-to-EBITDA of 0.02 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hansoh Pharmaceutical Group Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current Debt-to-EBITDA is 0.02, which is 33% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.52, compared to a current price of $4.11 — trading 16.8% above its estimated fair value. The current Debt-to-EBITDA is 0.02, which is 33% below median its 10-year median of 0.03 and 98.8% below the Drug Manufacturers industry median of 1.64. Hansoh Pharmaceutical Group Co's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Debt-to-EBITDA is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $4.11 is trading 16.8% above its estimated GF Value™ of $3.52.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
Debt-to-EBITDA: 0.02 (33% below median its 10-year median of 0.03)
GF Value™: $3.52 vs. price of $4.11 (16.8% above fair value)
Industry Position: 98.8% below the Drug Manufacturers median (#18 of 691)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
91GF Score
Get the complete analysis for HNSPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
